Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated ...

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines Provided by GlobeNewswire Apr 22, 2025 3:00am ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

At the time, GSK made a $300 million equity investment in 23andMe, which is more than the amount Regeneron could end up paying for the entire company.

Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment April 22, 2025 — 07:38 am EDT Written by RTTNews.com for RTTNews -> ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...

The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $8.43 per share.

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and ...

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness ...

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines Apr. 22, 2025 6:00 AM ET Regeneron Pharmaceuticals, Inc. (REGN) ...